Hook & thesis
Sagimet Biosciences (SGMT) just shifted from a binary-discovery story to a replication trade. Denifanstat already cleared a major regulatory and clinical hurdle in China - a rare outright Phase 3 win - and the company is now preparing to enroll roughly 800 U.S. patients for AURORA. That changes how the market should value the next big event: the U.S. trial is mostly about confirming the China result in a different population and regulatory environment, not about proving the molecule can work at all.
My trade: initiate a tactical short at $9.74, targeting $6.25 over a mid-term window (45 trading days). Put the stop at $11.45 to respect recent 52-week highs and the potential for headline-driven squeezes. This is a high-risk, defined-risk trade designed to capture a post-enrollment consolidation or an execution drift during the AURORA enrollment phase.
Why the market should care - business and fundamental driver
Sagimet is a clinical-stage company built around denifanstat, a once-daily oral FASN inhibitor. The drug is being pursued in two principal areas in the public data: MASH (nonalcoholic steatohepatitis) and acne. The recent investor narrative has increasingly focused on acne after the company reported a successful Phase 3 in China on 10/24/2025. Management has signaled that the U.S. AURORA Phase 3 trial will begin patient screening in October 2026 and will enroll approximately 800 U.S. patients, including about 450 adolescents - a sizable study that shifts the program from proof-of-concept to confirmatory.